Drugs / QLS12010
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06946641 | Mar → Dec 2025 overdue | atopic eczema, hidradenitis suppurativa, rheumatoid arthritis | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07344051 | Apr 2026 → Sep 2027 expected | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07417917 | Apr 2026 → Jun 2027 expected | autoinflammatory syndrome | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07377773 | Mar 2026 → Mar 2028 expected | rheumatoid arthritis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS12010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07344051 ↗ |
| Route | Oral | “QLS12010 oral capsule(s)” NCT06946641 ↗ |